2025
Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome?
Mestre-Bach G, Potenza M, Granero R, Håkansson A, Gómez-Peña M, Perales I, Vicó À, Uríszar J, Fernández-Aranda F, Sánchez I, Jiménez-Murcia S. Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome? Journal Of Behavioral Addictions 2025, 14: 465-479. PMID: 40116860, DOI: 10.1556/2006.2025.00023.Peer-Reviewed Original ResearchConceptsCognitive-behavioral therapyGambling disorderPornography useEmotion regulationGD severityTreatment outcomesCognitive-behavioral therapy approachCognitive-behavioral therapy sessionsTreatment outcomes of individualsCo-occurrence of GDCo-occurrenceMental health concernsImprove treatment adherenceBehavioral addictionsTreatment dropoutOutcomes of individualsWeekly sessionsTreatment adherencePsychopathologyGamblingSessionsDisordersAssociated with higher likelihoodRelapseImpulseEffect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials
Jerene D, van Kalmthout K, Levy J, Alacapa J, Deyanova N, Dube T, Mganga A, Tasca B, Bogdanov A, Efo E, Gamazina K, Garfin A, Kochanov V, Leung A, Madden N, Maraba N, McQuaid C, Mleoh L, Onjare B, Powers R, Terleiva Y, van Rest J, Gebhard A, Fielding K, Charalambous S. Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials. The Lancet 2025 PMID: 40086457, DOI: 10.1016/s0140-6736(24)02847-2.Peer-Reviewed Original ResearchDrug-susceptible tuberculosisTreatment outcomesPoor treatment outcomesPrimary outcomeDigital adherence technologiesIntervention armCluster randomised trialIntention-to-treat populationStandard of care armTuberculosis treatment outcomesDocumented treatment failureLoss to follow-upStandard of careAdherence technologiesTreatment failureTreatment startAdult patientsFollow-upPatientsTreatment statusPatient outcomesCare armTuberculosisMedicationTrialsKleptomania on the impulsive–compulsive spectrum. Clinical and therapeutic considerations for women
Munguía L, Baenas-Soto I, Granero R, Fábregas-Balcells M, Gaspar-Pérez A, Rosinska M, Potenza M, Cuquerella Á, Tapia-Martínez J, Cabús-Grange R, Taranilla-Castro A, Macharé-Alberni M, Talón-Navarro M, Fernández-Aranda F, Jiménez-Murcia S. Kleptomania on the impulsive–compulsive spectrum. Clinical and therapeutic considerations for women. Scientific Reports 2025, 15: 7886. PMID: 40050325, PMCID: PMC11885670, DOI: 10.1038/s41598-025-85705-9.Peer-Reviewed Original ResearchConceptsImpulsive-compulsive spectrumDSM-5 criteriaClinical groupsDSM-5Personality featuresSemi-structured clinical interviewTreatment outcomesHarm avoidance scoresCognitive behavioral treatmentHealthy control individualsSample of female patientsImpact treatment outcomesPoor treatment outcomesCompulsive featuresBehavioral treatmentHigher impulsivityAvoidance scoresClinical interviewKleptomaniaInvestigate treatment outcomesCharacteristics of peopleFemale participantsPsychopathologyClinical samplesTreatment approachesPrescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial
Mobley A, Wegman M, Bazazi A, Shenoi S, Bromberg D, Ahmad A, Kamarulzaman A, Altice F. Prescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial. International Journal Of Drug Policy 2025, 137: 104733. PMID: 39923270, PMCID: PMC11875876, DOI: 10.1016/j.drugpo.2025.104733.Peer-Reviewed Original ResearchConceptsLinkage to HIV careHIV careIncrease linkage to HIV careTreatment-as-prevention strategiesHIV treatment cascadeHIV treatment outcomesOpen-label trialCox proportional hazards modelsPatient preference trialOpioid use disorderMalaysia’s largest prison.Impact of methadoneProportional hazards modelTreatment cascadeInverse probability weighted Cox proportional hazards modelAnalytic sampleStudy participantsCareTreatment outcomesPrescribed methadoneOpioidConfounding variablesHIVUse disorderHazards modelColonic Manometry in Pediatric Patients with Spina Bifida: Results from a Retrospective Cohort Study
Shan A, Duel B, Phillips T, Buchanan P, Rodriguez L, Patel D. Colonic Manometry in Pediatric Patients with Spina Bifida: Results from a Retrospective Cohort Study. Children 2025, 12: 184. PMID: 40003286, PMCID: PMC11854801, DOI: 10.3390/children12020184.Peer-Reviewed Original ResearchSlow transit constipationRetrospective cohort studyColonic transit timeColonic manometryBowel dysfunctionColonic motilityAnorectal manometryAnorectal dysfunctionSB patientsStimulant laxativesCohort studySpina bifidaNeurogenic bowel dysfunctionDefecation-related symptomsEvaluate colonic motilityConservative therapyPediatric patientsSurgical interventionInvasive testingBowel regimensBowel symptomsFurther treatmentCM findingsTreatment outcomesDiagnostic findingsIdentification and external validation of a problem cannabis risk network
Lichenstein S, Kiluk B, Potenza M, Garavan H, Chaarani B, Banaschewski T, Bokde A, Desrivières S, Flor H, Grigis A, Gowland P, Heinz A, Brühl R, Martinot J, Paillère Martinot M, Artiges E, Nees F, Orfanos D, Poustka L, Hohmann S, Holz N, Baeuchl C, Smolka M, Vaidya N, Walter H, Whelan R, Schumann G, Pearlson G, Yip S. Identification and external validation of a problem cannabis risk network. Biological Psychiatry 2025 PMID: 39909136, DOI: 10.1016/j.biopsych.2025.01.022.Peer-Reviewed Original ResearchAlcohol use outcomesCannabis useNeural mechanismsSample of treatment-seeking adultsNeural mechanisms of riskTreatment-seeking adultsCannabis use disorderNon-clinical sampleMechanisms of riskFunctional connectivity dataSample of adolescentsTreatment outcomesAssociated with harmful outcomesPoor treatment outcomesAddiction severityUse disorderEmerging adulthoodWhole-brainCannabisCollege studentsBrain developmentConnectivity dataIdentified networksTreatment approachesAdultsT107 Beyond Rest: Unraveling the Nexus of Sleep Deficiency, Environment, Control, and their Influence on Opioid Use Disorder Treatment Outcomes
Elumn J, Cohen I, JadKarim L, Puglisi L, Lin H, Fiellin D, Yaggi K, Wang E. T107 Beyond Rest: Unraveling the Nexus of Sleep Deficiency, Environment, Control, and their Influence on Opioid Use Disorder Treatment Outcomes. Drug And Alcohol Dependence 2025, 267: 111875. DOI: 10.1016/j.drugalcdep.2024.111875.Peer-Reviewed Original ResearchFinding the optimal length of stay for veterans in substance use disorder residential treatment using generalized propensity score modeling
Dams G, Gross G, Ketchen B, Smith N, Burden J. Finding the optimal length of stay for veterans in substance use disorder residential treatment using generalized propensity score modeling. International Journal Of Drug Policy 2025, 137: 104715. PMID: 40024631, DOI: 10.1016/j.drugpo.2025.104715.Peer-Reviewed Original ResearchConceptsSubstance use disordersResidential treatmentSevere substance use disordersTreatment outcomesComplex clinical needsVeterans AffairsResidential programsLength of stayDepartment of Veterans AffairsOptimal length of stayResidential centersMethodological issuesVeteransEnhanced outcomesClinical assessmentIndividual patient needsGeneralized propensity score modelComputational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins
Strigari L, Schwarz J, Bradshaw T, Brosch-Lenz J, Currie G, El-Fakhri G, Jha A, Mežinska S, Pandit-Taskar N, Roncali E, Shi K, Uribe C, Yusufaly T, Zaidi H, Rahmim A, Saboury B. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins. Journal Of Nuclear Medicine 2025, jnumed.124.268186. PMID: 39848769, DOI: 10.2967/jnumed.124.268186.Peer-Reviewed Original ResearchRadiopharmaceutical therapyNuclear oncologySociety of Nuclear MedicinePredictive dosimetryDosimetric informationTreatment planningTreatment outcomesLack of reimbursementTreatment personalizationDose responseTreatment optimizationEtiological mechanismsRobust security measuresPatient consentReal-world systemsNuclear medicineCross-border data sharingPatientsTreatmentEthical approvalCorrelates of Impaired Sleep Duration Among Adults With Trauma Alone and With Posttraumatic Stress Disorder
Havlik J, Rhee T, Rosenheck R. Correlates of Impaired Sleep Duration Among Adults With Trauma Alone and With Posttraumatic Stress Disorder. Psychological Trauma Theory Research Practice And Policy 2025 PMID: 39836166, DOI: 10.1037/tra0001846.Peer-Reviewed Original ResearchImpaired sleep durationStress disorderSleep durationEffect sizePosttraumatic stress disorderClinically meaningful effect sizesNational Epidemiologic SurveyMeaningful effect sizesPsychiatric multimorbidityPTSDTrauma/PTSDImprove treatment outcomesMedical comorbiditySleep disturbanceImpaired sleepBehavioral variablesTreatment outcomesAllostatic loadNationally representative sampleAdjusted multivariable regressionEpidemiological surveyDisordersBody mass indexRepresentative sampleSleepPhenotypic variability in phosphate transport disorders highlights need for individualized treatment strategies
Zhu Z, Bergwitz C. Phenotypic variability in phosphate transport disorders highlights need for individualized treatment strategies. Kidney International 2025, 107: 12-15. PMID: 39746740, DOI: 10.1016/j.kint.2024.10.020.Peer-Reviewed Original ResearchConceptsPhosphate-wasting disordersIndividualized treatment strategiesLong-term outcomesGenetic variantsPathogenic variantsPhenotypic variabilitySLC34A3 geneClinical presentationTreatment strategiesTreatment challengesTransport disordersTreatment outcomesAffected individualsTherapeutic strategiesPotential treatment challengesBiochemical profileVariantsDisordersGenesOutcomesPhenotypeNpt2cSLC34A3Npt2aChapter 52 Obsessive–compulsive disorder
Abdallah S, Olfson E, Fernandez T. Chapter 52 Obsessive–compulsive disorder. 2025, 937-950. DOI: 10.1016/b978-0-443-19176-3.00011-x.ChaptersObsessive-compulsive disorderObsessive-compulsive disorder etiologiesCognitive behavioral therapySerotonin reuptake inhibitorsReuptake inhibitorsBehavioral therapyMedication augmentationNeuroanatomical alterationsNeurochemical imbalanceMedication trialsGenetic influencesImprove treatment outcomesEvidence-based therapeutic strategiesTreatment outcomesRobust clinical trialsDisordersClinical manifestationsTreatment optionsClinical trialsTherapeutic strategiesSerotoninMultifactorial naturePharmacotherapyNeuromodulationTrials
2024
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors
Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Jiménez‐Yuste V, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery‐Singleton T, Bonzo D, Mitchell I, Wilkinson T, Young G. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia 2024, 31: 78-86. PMID: 39676340, PMCID: PMC11780187, DOI: 10.1111/hae.15109.Peer-Reviewed Original ResearchConceptsIncidence of rebleedingLow incidence of rebleedingEptacog betaBleeding episodesHemophilia ALow incidenceInitial dosing strategyControl of bleedingIntention-to-treat analysisReview treatment outcomesRecombinant FVIIaDosing strategiesRebleeding incidenceAdolescent patientsBleeding controlBleeding treatmentRebleedingRebleedPatient populationTreatment outcomesTreatment dataHemophiliaBleedingPerioperative carePatientsTransformation of the HIV treatment cascade for people who inject drugs in Ukraine
Bromberg D, Rhoades D, Madden L, Ivasiy R, Meteliuk A, Pykalo I, Filippovych M, Nikitin B, Farnum S, Fomenko T, Dvoriak S, Altice F. Transformation of the HIV treatment cascade for people who inject drugs in Ukraine. AIDS 2024, 39: 306-311. PMID: 39589135, DOI: 10.1097/qad.0000000000004056.Peer-Reviewed Original ResearchOpioid agonist therapyAntiretroviral therapyImprove HIV treatment outcomesHIV treatment outcomesHIV care cascadeCross-sectional biobehavioral surveyTreatment outcomesCare cascadeUkraine's HIV epidemicPrescription of antiretroviral therapyPrescribed antiretroviral therapyAdherence to antiretroviral therapyHIV treatment cascadeAgonist therapyBiobehavioral surveyOpioid dependenceHIV diagnosisTreatment cascadeHIV epidemicHIVOpioidPWIDTherapyDrugOutcomesAcute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them
Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.Peer-Reviewed Original ResearchAcute promyelocytic leukemiaAdvent of all-trans retinoic acidEarly mortalityLong-term treatment toxicitiesArsenic trioxidePromyelocytic leukemiaClinical practiceIncidence of acute promyelocytic leukemiaRates of remissionLong-term outcomesTreatment of acute promyelocytic leukemiaLong-term survivalComprehensive patient evaluationResource-limited settingsTreatment toxicityAll-trans retinoic acidDelayed diagnosisPatient demographicsSignificant comorbiditiesTreatment initiationOlder patientsExpert centersClinical trialsTreatment outcomesReal-world settingsOVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis
Kern R, Kuang C, Seshagiri C, Konisky A, Galley A, Boasso A, Hempel E, Malchano Z, Vaughan B, Cimenser A, Da X, Shpokayte M, Hajos M. OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis. Alzheimer's & Dementia 2024, 20: e085091. PMCID: PMC11714597, DOI: 10.1002/alz.085091.Peer-Reviewed Original ResearchRandomized controlled trialsAPOE4 carrier statusBaseline subgroupsMild-moderate Alzheimer's diseasePhase 2 clinical trialIndicators of neurodegenerationBrain atrophyBrain volume outcomesBaseline ageBrain volume lossWhole brain volume lossCarrier statusWBVMagnetic resonance imagingAlzheimer's diseaseBaseline covariatesMonth 6Subgroup analysisAt-homeParticipantsClinical trialsTreatment outcomesActive treatmentOne-hourSham treatmentUtilization of Prognosis Assignment: A Cross-Sectional Survey of Military Periodontists
Sawaya R, Dickens N, Merchant K, Wilson J, Darcey C. Utilization of Prognosis Assignment: A Cross-Sectional Survey of Military Periodontists. Military Medicine 2024, 190: e649-e656. PMID: 39576235, DOI: 10.1093/milmed/usae496.Peer-Reviewed Original ResearchPeriodontal prognosisDental readinessTreatment outcomesDental readiness classificationClinical practicePrediction of treatment outcomePeriodontal consultationTreatment outcome predictionDental literaturePeriodontistsRetrospective evaluation of treatmentPresentation severityEvaluation of treatmentTreatment planningPrognosisRetrospective evaluationMilitary service branchMultiple time pointsOutcome predictionCross-sectional surveyTime pointsPracticing cliniciansTreatmentDemographic informationSeverityDeep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer
Xia Y, Zhou J, Xun X, Johnston L, Wei T, Gao R, Zhang Y, Reddy B, Liu C, Kim G, Zhang J, Zhao S, Yu Z. Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer. Npj Precision Oncology 2024, 8: 263. PMID: 39551847, PMCID: PMC11570623, DOI: 10.1038/s41698-024-00754-z.Peer-Reviewed Original ResearchProgression-free survivalCT scanLiver cancerAccurate treatment response assessmentResponse evaluationMetastatic organ sitesOncological treatment outcomesResponse Evaluation CriteriaLow-risk patientsTreatment response assessmentTreatment response evaluationTreatment response classificationAdvanced liver cancerStratify high-riskMultifocal hepatic lesionsTreatment outcome assessmentEvaluation of responseOverall survivalEvaluation CriteriaInternal five-fold cross-validationOncology clinical trialsResponse assessmentSolid tumorsClinical trialsTreatment outcomesPlasma NGAL, not IFN-γ, predicts early treatment response in drug-naïve Chinese Han schizophrenia patients
Sun X, Li M, Qiu Y, Su Q, Wang J, Bi F, Li J. Plasma NGAL, not IFN-γ, predicts early treatment response in drug-naïve Chinese Han schizophrenia patients. Schizophrenia Research 2024, 274: 457-463. PMID: 39515255, DOI: 10.1016/j.schres.2024.10.025.Peer-Reviewed Original ResearchDrug-naive schizophrenia patientsSchizophrenia patientsNeutrophil gelatinase-associated lipocalinNeutrophil gelatinase-associated lipocalin concentrationsEarly treatment responseDuration of untreated illnessTreatment responseIFN-gHealthy controlsNGAL concentrationsEarly prediction of treatment efficacyPlasma neutrophil gelatinase-associated lipocalinNeutrophil gelatinase-associated lipocalin levelsUntreated illnessPrediction of treatment efficacyPredicting early treatment responsePlasma NGAL concentrationsWeeks of treatmentIFN-g levelsPersonalized treatment strategiesLogistic regression analysisBaseline NGAL concentrationLongitudinal studySchizophreniaTreatment outcomesDevelopment of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies
Dickson S, Mallinckrodt C, Rogula B, Powell L, Potashman M, Coric V, L’Italien G, Hendrix S. Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies. Neurology And Therapy 2024, 13: 1627-1639. PMID: 39287752, PMCID: PMC11541966, DOI: 10.1007/s40120-024-00661-2.Peer-Reviewed Original ResearchComposite scaleDisease-modifying therapiesItem-level dataDisease progressionDetect clinically meaningful effectsPlacebo arm dataValidity scalesMeasure disease progressionTreatment effectsClinical declineDMT effectClinically meaningful effectChange scoresAssess treatment effectsDetect disease progressionTreatment outcomesSlow disease progressionMeaningful effectSensitive to disease progressionNeurodegenerative disease progressionItemsResponse outcomesPatient populationStandard itemsNatural history data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply